Company: STAA
Filing Date: 2025-11-03
Form Type: PX14A6G
Source: 0001193125-25-261591
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-11-03
Form: PX14A6G
Chunk 1
---
25510 Commercentre Drive Lake Forest, CA 92630 Dear Members of the Board: We are writing to express our deep concern regarding the Board’s decision to postpone the special meeting of stockholders of STAAR to December 3, 2025. The Company’s sudden adjournment of the special meeting scheduled for October 23 and this most recent postponement – both without any substantive explanation – indicate that the Board is attempting to revive a transaction that shareholders have already clearly signaled they do not support. Shareholders have already delivered their verdict.Recent media coverage reported that, ahead of the special meeting scheduled for October 23, 2025, approximately 72% of STAAR’s outstanding shares had voted againstthe merger, and that approximately 81% had voted againstthe $55 million compensation package for STAAR’s executives. 1In addition, all three leading proxy advisory firms – ISS, Glass Lewis, and Egan-Jones – have recommended voting against the merger. The Board’s role is to act in the best interests of shareholders. Rather than respecting the overwhelmingly and clearly expressed will of the shareholder base, the Board appears to be prolonging a process that lacks shareholder support and is no longer viable. No progress has been disclosed from STAAR’s latest discussions with Alcon.The Company’s most recent public filings reveal that STAAR and Alcon initiated renewed discussions in mid-Octoberto consider “recent developments and potential next steps.” However, shareholders have seen no indication of actual progress in the way of improved terms. According to the Company’s latest amendment to its proxy statement, as recently as October 24, 2025, Alcon had provided no commitment to increasing the consideration offered to shareholders. The only material development disclosed to shareholders has been the postponement of the special meeting to vote on the proposed merger. This lack of progress reinforces our concern that the current process and framework are not capable of producing the best value outcome for shareholders.

The Board must now prioritize its fiduciary duties. Continued delays create uncertainty,
distract management, and risk further harm to the Company and its shareholders. The Board should not allow procedural maneuvering to substitute for sound judgment. We urge the Board to acknowledge the outcome that shareholders have already signaled
and to take steps consistent with its fiduciary obligations to protect and enhance shareholder value.

It is also becoming increasingly clear that the
Board’s composition would benefit from additional shareholder perspective and membership of a director with meaningful economic interests in the Company. I would be pleased to serve on the Board with you